ATE347904T1 - Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert - Google Patents

Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Info

Publication number
ATE347904T1
ATE347904T1 AT99956777T AT99956777T ATE347904T1 AT E347904 T1 ATE347904 T1 AT E347904T1 AT 99956777 T AT99956777 T AT 99956777T AT 99956777 T AT99956777 T AT 99956777T AT E347904 T1 ATE347904 T1 AT E347904T1
Authority
AT
Austria
Prior art keywords
associated antigens
cancer
universal tumor
antigens including
htert
Prior art date
Application number
AT99956777T
Other languages
English (en)
Inventor
Lee M Nadler
William C Hahn
Joachim L Schultze
Robert H Vonderheide
Original Assignee
Dana Farber Cancer Inst Inc
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22309530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347904(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc, Whitehead Biomedical Inst filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE347904T1 publication Critical patent/ATE347904T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT99956777T 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert ATE347904T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10610698P 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
ATE347904T1 true ATE347904T1 (de) 2007-01-15

Family

ID=22309530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956777T ATE347904T1 (de) 1998-10-29 1999-10-29 Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert

Country Status (7)

Country Link
US (1) US7851591B1 (de)
EP (1) EP1126872B1 (de)
AT (1) ATE347904T1 (de)
AU (1) AU1331100A (de)
CA (1) CA2344972A1 (de)
DE (1) DE69934426T2 (de)
WO (1) WO2000025813A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1171612A2 (de) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-spezifisches krebsimpfstoff
WO2001035810A2 (en) * 1999-11-15 2001-05-25 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using cytochrome p450 1b1
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
AU2003202908A1 (en) 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
CN1306027C (zh) * 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
EP1765988B1 (de) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Neue künstliches antigen präsentierende zellen und verwendungen dafür
EP1781313A4 (de) 2004-06-17 2009-08-26 Beckman Coulter Inc Mycobacterium tuberculosis epitope und anwendungsverfahren dafür
WO2009125394A1 (en) 2008-04-09 2009-10-15 Technion Research & Development Foundation Ltd. Anti human immunodeficiency antibodies and uses thereof
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
EP2536830B1 (de) * 2010-02-16 2019-07-17 Ultimovacs AS Polypeptide
EP2388014A1 (de) * 2010-05-21 2011-11-23 Dorkoosh, Farid Abedin Therapeutische Anwendung von tumoralen Peptiden mit variabler Immunoglobulinregion bei Patienten mit B-Zell-Malignomen
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP7781511B2 (ja) 2016-09-30 2025-12-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法
WO2019210055A2 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5686068A (en) 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US5747317A (en) * 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
DE69723531T3 (de) 1996-10-01 2012-09-06 Geron Corp. Katalytische Untereinheit der menschlichen Telomerase
WO1998037181A2 (en) 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
CA2347067C (en) * 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase

Also Published As

Publication number Publication date
CA2344972A1 (en) 2000-05-11
DE69934426T2 (de) 2007-10-04
EP1126872A1 (de) 2001-08-29
EP1126872A4 (de) 2003-01-02
AU1331100A (en) 2000-05-22
WO2000025813A1 (en) 2000-05-11
DE69934426D1 (de) 2007-01-25
US7851591B1 (en) 2010-12-14
EP1126872B1 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
ATE347904T1 (de) Krebsimmuntherapie und krebsdiagnose unter verwendung universeller tumorassoziierter antigene einschliesslich htert
DK1349870T3 (da) Sammensætninger til terapien og diagnosen af ovariecancer
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
EP1187591A4 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
IL195338A0 (en) Optimized fc variants and methods for their generation
ZA945364B (en) Antibodies specific for human prostate glandular kallikrein
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
DE69924826D1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
MXPA05014016A (es) Proteinas portadoras para vacunas.
DK0948518T3 (da) Isoleret nucleinsyremolekyle kodende for et cancer-associeret antigen, selve antigenet samt anvendelser deraf
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
MY150237A (en) Cripto blocking antibodies and uses thereof
CY1110695T1 (el) Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων
DE69939820D1 (de) Internalisierende erbb2 antikörper
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
NO992916D0 (no) Fosfodiesterase 8A
WO1999067384A3 (en) Prostate cancer-associated genes
EP1230932A3 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO2000060080A3 (en) Molecules of the immune system
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
UY26170A1 (es) Antigeno (c42) asociados a tumores

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties